Clinical trials: Castration-Resistant Prostate Carcinoma
Prostate Cancer Metastatic, Castration-resistant Prostate Cancer
Exercise for Advanced Prostate Cancer: a Multicomponent Feasibility Trial
This feasibility study will investigate whether men with metastatic prostate cancer can take part in and progress through a home-based exercise program.
- Trial name
- EXACT (NCT03658486)
- Testing
- Exercise
- Where
- United Kingdom
- Volunteers
- 30 people
- Sponsor
- Queen's University, Belfast
Prostate Cancer
Docetaxel and Prednisone With/Out OGX-011 in Recurrent or Metastatic Prostate Cancer That Did Not Respond to Previous Hormone Therapy
RATIONALE: Drugs used in chemotherapy, such as docetaxel and prednisone, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00258388
- Testing
- custirsen sodium, docetaxel, prednisone
- Where
- 13 sites in United States, Canada
- Volunteers
- 82 people
- Sponsor
- NCIC Clinical Trials Group
Adenocarcinoma of the Prostate, Hormone-resistant Prostate Cancer
Orteronel in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
This phase II trial studies how well orteronel works in treating patients with metastatic hormone-resistant prostate cancer. Orteronel may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
- Conditions
- Adenocarcinoma of the Prostate, Hormone-resistant Prostate Cancer, Recurrent Prostate Cancer, Stage IV Prostate Cancer
- Trial name
- NCT01866423
- Testing
- orteronel, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- University of Southern California
Metastatic Cancer, Prostate Cancer
S0421, Docetaxel and Prednisone With or Without Atrasentan in Treating Patients With Stage IV Prostate Cancer and Bone Metastases That Did Not Respond to Previous Hormone Therapy
RATIONALE: Drugs used in chemotherapy, such as docetaxel, prednisone, and atrasentan work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00134056
- Testing
- atrasentan hydrochloride, docetaxel, prednisone
- Where
- 554 sites in United States
- Volunteers
- 1,038 people
- Sponsor
- SWOG Cancer Research Network
Metastatic Castrate-Resistant Prostate Cancer (mCRPC)
Investigating SX-682 in Combination With Apalutamide in Metastatic Castration-resistant Prostate Cancer
ASpiRE will investigate the effect of the drug SX-682 in combination with Apalutamide in men suffering from metastatic castration-resistant prostate cancer (mCRPC).
- Trial name
- ASpiRE (NCT07002320)
- Testing
- SX-682, Apalutamide
- Where
- 4 sites in Switzerland, United Kingdom
- Volunteers
- 78 people
- Sponsor
- Institute of Cancer Research, United Kingdom
PSMA-Positive Progressive Metastatic Castration-Resistant Prostate Cancer
A Phase III Study Comparing HRS-4357 With Novel Androgen Receptor Pathway Inhibitors in Patients With Progressive, PSMA-Positive Metastatic Castration-Resistant Prostate Cancer
This study is a randomized, open-label, controlled, multicenter phase III clinical trial, which plans to randomly enroll 370 subjects with advanced metastatic castration-resistant prostate cancer (mCRPC).
- Trial name
- NCT07311694
- Testing
- HRS-4357 injection, Enzalutamide；Abiraterone
- Where
- China
- Volunteers
- 370 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Metastatic Castration-resistant Prostate Cancer
Study of Enzalutamide in Patients With Castration-resistant Prostate Cancer
This research study is evaluating a drug called enzalutamide in metastatic castration resistant prostate cancer. Enzalutamide is already FDA approved for metastatic castration resistant prostate cancer after treatment with…
- Trial name
- NCT01942837
- Testing
- Enzalutamide
- Where
- 5 sites in United States
- Volunteers
- 67 people
- Sponsor
- Dana-Farber Cancer Institute
Metastatic Castration-resistant Prostate Cancer (mCRPC)
Lutetium (177Lu) DGUL Combined With Pembrolizumab in Metastatic Castration-Resistant Prostate Cancer
The goal of this clinical trial is to evaluate the safety of the combination therapy of Lutetium (177Lu) DGUL and pembrolizumab.
- Trial name
- NCT07244393
- Testing
- Lutetium (177Lu) DGUL, Pembrolizumab
- Where
- South Korea
- Volunteers
- 30 people
- Sponsor
- Cellbion Co., Ltd.
Castration-Resistant Prostate Cancer (CRPC), Colorectal Cancer
177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors
This is a Phase 1/2a dose escalation and expansion study to determine the safety, tolerability, and preliminary clinical activity of 177LuBetaBart, a lutetium-labeled anti-B7-H3 monoclonal antibody, in patients with…
- Conditions
- Castration-Resistant Prostate Cancer (CRPC), Colorectal Cancer, NSCLC (Non-small Cell Lung Cancer), Ovarian Cancer
- Trial name
- BetaBart (NCT07189871)
- Testing
- 177Lu-BetaBart, BetaBart + unlabeled BetaBart
- Where
- 5 sites in United States
- Volunteers
- 61 people
- Sponsor
- Radiopharm Theranostics, Ltd
Adenocarcinoma of the Prostate, Recurrent Prostate Cancer
Treating Patients With Metastatic Prostate Cancer Not Responding to Hormone and Chemotherapy
This phase I/II trial is studying the side effects and best dose of ixabepilone and mitoxantrone hydrochloride when given together with prednisone and to see how well they work in treating patients with metastatic prostate cancer…
- Conditions
- Adenocarcinoma of the Prostate, Recurrent Prostate Cancer, Stage IV Prostate Cancer
- Trial name
- NCT00331344
- Testing
- mitoxantrone hydrochloride, ixabepilone, prednisone
- Where
- 2 sites in United States
- Volunteers
- 100 people
- Sponsor
- National Cancer Institute (NCI)
Castration-Resistant Prostate Carcinoma, Metastatic Malignant Neoplasm in the Bone
Impact of DNA Repair Pathway Alterations on Sensitivity to Radium-223 in Bone Metastatic Castration-resistant Prostate Cancer
This study investigates how well radium-223 works in treating patients with castration-resistant prostate cancer than has spread to the bones (bone metastases).
- Conditions
- Castration-Resistant Prostate Carcinoma, Metastatic Malignant Neoplasm in the Bone, Metastatic Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8
- Trial name
- NCT04489719
- Testing
- Biospecimen Collection, Questionnaire Administration, Radium Ra 223 Dichloride
- Where
- 4 sites in United States
- Volunteers
- 48 people
- Sponsor
- University of Washington
Prostate Cancer, Recurrent Prostate Carcinoma
Biomarker-Driven Therapy With Nivolumab and Ipilimumab in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Expressing AR-V7
This phase II trial studies how well nivolumab and ipilimumab work in treating patients with hormone-resistant prostate cancer that has spread to other places in the body and express androgen receptor-variant-7 (AR-V7).
- Conditions
- Prostate Cancer, Recurrent Prostate Carcinoma, Stage IV Prostate Adenocarcinoma
- Trial name
- STARVE-PC (NCT02601014)
- Testing
- Ipilimumab, Nivolumab, Enzalutamide
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Metastatic Castration-resistant Prostate Cancer, Metastatic Prostate Cancer
Platinum and Taxane Chemo in Met Castration Resistant Prostate Cancer Patients With Alterations in DNA Damage Response Genes
The usual approach for most patients who are not in a study is treatment with docetaxel. This study is being done to answer the following question: Can the chance of prostate cancer growing or spreading be lowered by adding a…
- Trial name
- OPTION-DDR (NCT06439225)
- Testing
- Docetaxel, Carboplatin
- Where
- 14 sites in Canada
- Volunteers
- 236 people
- Sponsor
- Canadian Cancer Trials Group
Prostatic Neoplasms
Abiraterone Acetate in Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy
This is a phase 3 study to compare the clinical benefit of abiraterone acetate plus prednisone with placebo plus prednisone in patients with metastatic castration-resistant prostate cancer (CRPC) who have failed one or two…
- Trial name
- NCT00638690
- Testing
- Abiraterone acetate, Prednisone/prednisolone
- Where
- 127 sites in United States, Australia and 10 more
- Volunteers
- 1,195 people
- Sponsor
- Cougar Biotechnology, Inc.
Advanced and/or Metastatic Solid Tumours
A Phase I Study to Assess PSMA+ and PSMA- Tumour Lesions
CB307 is a trispecific Humabody® targeting CD137; PSMA; and human serum albumin (HSA) undergoing Phase 1 assessment in patients with PSMA+ solid tumours.
- Trial name
- NCT05836623
- Testing
- Radiolabelled CB307, CB307
- Where
- Netherlands
- Volunteers
- 5 people
- Sponsor
- Crescendo Biologics Ltd.
Prostate Cancer, Neoplasm Metastasis
BAY88-8223, Dose Finding Study in Patients With HRPC
The purpose of this study is to evaluate the effectiveness of the investigational radioisotope Radium-223, Alpharadin, in treatment of men with prostate cancer and bone metastases that no longer respond to hormonal treatment.
- Trial name
- NCT00337155
- Testing
- Radium-223 dichloride (BAY88-8223)
- Where
- United Kingdom
- Volunteers
- 122 people
- Sponsor
- Bayer
Prostatic Neoplasms
Gallium-68 Citrate PET Used in Prostate Cancer
This is a single center, pilot, cross-sectional imaging study investigating the use of gallium-68 citrate PET in participants with metastatic castration-resistant prostate cancer who are planning to undergo a metastatic tumor…
- Trial name
- NCT02391025
- Testing
- Gallium-68 citrate, Positron Emission Tomography (PET)
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- Rahul Aggarwal
Prostate Cancer
LEE011 (Ribociclib) in Combination With Docetaxel Plus Prednisone in mCRPC
This is a Phase Ib/II open label clinical trial in patients with metastatic castration resistant prostate cancer. The objective of the phase Ib portion of the study is to establish the maximum tolerated dose (MTD) and dose…
- Trial name
- NCT02494921
- Testing
- Docetaxel-PNP, Ribociclib, Prednisone
- Where
- 6 sites in United States
- Volunteers
- 43 people
- Sponsor
- Rahul Aggarwal
Prostate Cancer
A Study to Learn More About How Radium-223 Affects the Quality of Life of Colombian Patients With Prostate Cancer That Has Not Responded to Testosterone Lowering Treatment and Has Spread to the Bones, and to Better Understand Its Safety
The study drug, radium-223, gives off radiation that helps to kill cancer cells in the prostate. It is already available for patients to receive as a treatment for prostate cancer that has not responded to testosterone lowering…
- Trial name
- QOLRAD (NCT04681144)
- Testing
- Radium-223-dichloride (Xofigo, BAY88-8223)
- Where
- Colombia
- Volunteers
- 103 people
- Sponsor
- Bayer
Metastatic Breast Cancer, Metastatic Prostate Cancer
Prevention of Symptomatic Skeletal Events With Denosumab Administered Every 4 Weeks Versus Every 12 Weeks
The aim of the trial is to test the hypothesis that the benefit of denosumab is maintained if administered only every 12 weeks as compared to every 4 weeks.
- Conditions
- Metastatic Breast Cancer, Metastatic Prostate Cancer, Bone Metastases
- Trial name
- NCT02051218
- Testing
- Denosumab (reduced dosing), Denosumab (standard dosing)
- Where
- 50 sites in Austria, Germany and 1 more
- Volunteers
- 1,380 people
- Sponsor
- Swiss Cancer Institute